GIA
TEVA icon

Gateway Investment Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Gateway Investment Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
9,875
+121
+1% +$4.03K ﹤0.01% 687
2026
Q1 		$294K Sell
9,754
-30,120
-76% -$969K ﹤0.01% 615
2025
Q4 		$1.24M Buy
39,874
+29
+0.1% +$714 0.01% 350
2025
Q3 		$805K Sell
39,845
-69,179
-63% -$1.22M 0.01% 361
2025
Q2 		$1.83M Buy
109,024
+60,308
+124% +$973K 0.02% 259
2025
Q1 		$749K Buy
48,716
+7,749
+19% +$138K 0.01% 359
2024
Q4 		$903K Sell
40,967
-915
-2% -$16.6K 0.01% 332
2024
Q3 		$755K Hold
41,882
– – 0.01% 350
2024
Q2 		$681K Hold
41,882
– – 0.01% 363
2024
Q1 		$591K Hold
41,882
– – 0.01% 379
2023
Q4 		$437K Buy
41,882
+9,312
+29% +$86.9K 0.01% 399
2023
Q3 		$332K Buy
+32,570
New +$303K ﹤0.01% 417

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Gateway Investment Advisers's TEVA Position: Q2 2026 in Review

Gateway Investment Advisers increased its Teva Pharmaceuticals (TEVA) stake by 1.2% in Q2 2026, buying an estimated $4.03K and bringing the position to 9,875 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #687.

Gateway Investment Advisers first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.83M in Q2 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Gateway Investment Advisers held 9,875 shares of Teva Pharmaceuticals worth $335K as of Q2 2026.
  • Gateway Investment Advisers bought 121 Teva Pharmaceuticals shares in Q2 2026, an estimated $4.03K.
  • Teva Pharmaceuticals made up ﹤0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #687 holding.
  • Gateway Investment Advisers first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Gateway Investment Advisers's Teva Pharmaceuticals position peaked at $1.83M in Q2 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.